Nevertheless, despite similarities in study design, access criteria, and dose of rolofylline, the primary trial reported here didn’t replicate the findings of the pilot trial. Several known reasons for this discordance warrant thought. The protocol underwent many revisions. First, one of the inclusion requirements for the current trial, however, not for the pilot trial, was an elevated level of human brain natriuretic peptide or N-terminal pro-brain natriuretic peptide; nonetheless, almost 80 percent of the sufferers in the pilot trial would have qualified for today’s trial. Second, the criterion for successful treatment was transformed from a physician-directed switch from intravenous to oral diuretics to patient-reported improvement in symptoms. Nonetheless, rolofylline was connected with an increased rate of achievement than placebo significantly.The recipient of the AGA-Athena Troxel Blackburn Study Scholar Award in Neuroenteric Disease will be selected by the AGA Study Awards Panel in accordance with AGA Institute policies and practices governing research grants.. Agilent Systems introduces SureSelect Individual All Exon v2 Target Enrichment kit for malignancy assay Agilent Technologies Inc. today launched the SureSelect Human All Exon v2 Target Enrichment kit, which was developed in close collaboration with the Broad Institute of Harvard and MIT. The kit, the 15th SureSelect product in Agilent’s portfolio, is an individual tube assay that allows experts to streamline experiments by sequencing the expressed genome while discarding regions not of interest. This year alone, the SureSelect Focus on Enrichment System provides been cited in eight papers covering study into a wide range of heritable disorders.